Se connecter Inscription gratuite

AC Immune SA Propriété du management

Quel est le Propriété du management de AC Immune SA?

Le Propriété du management de AC Immune SA est 47.74%

Quelle est la définition de Propriété du management?



La propriété d'un initié est calculée en divisant le nombre total d'actions possédées par des initiés (actionnaires détenant plus de 5% de la société ou un dirigeant ou un administrateur de la société) par le nombre total d'actions en circulation.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Propriété du management des entreprises dans Health Care secteur sur NASDAQ par rapport à AC Immune SA

Que fait AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Entreprises avec propriété du management similaire à AC Immune SA